Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1
Brief Summary: This study will evaluate the efficacy, safety and tolerability of danoprevir (RO5190591) plus ritonavir as compared to danoprevir alone or placebo plus ritonavir in patients with chronic hepatitis C genotype 1 receiving Pegasys (peginterferon alfa-2a) and ribavirin. Patients in cohorts will be randomized to receive either oral doses of danoprevir, or danoprevir plus ritonavir, or placebo plus ritonavir. All patients will receive Pegasys (180mcg sc once weekly) plus ribavirin (1000-1200mg/day po), with the option to continue this treatment after completion of study drug treatment. Anticipated time on study treatment is up to 12 weeks.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin, Drug: ritonavir | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: peginterferon alfa-2a [Pegasys], Drug: placebo, Drug: ribavirin, Drug: ritonavir | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: peginterferon alfa-2a [Pegasys]; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: ritonavir; Assigned to Arm(s): B, C
B: Arm Label: GT1 HCV 10-mg Elbasvir (Panel A); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GTI HCV 50-g Elbasvir (Panel B); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1 HCV 5-mg Elbavir (Panel C); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1 HCV 200-mg Elbasvir (Panel D); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 10-mg Elbasvir (Panel E); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 50-mg Elbasvir (Panel F); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 100-mg Elbasvir (Panel G); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT3 HCV 200-mg Elbasvir (Panel H); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1a HCV 10-mg Elbasvir (Panel I); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Arm Label: GT1a HCV 50-mg Elbasvir (Panel J); Type: EXPERIMENTAL; Interventions: Drug: Elbasvir, Drug: Placebo | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): GT1 HCV 10-mg Elbasvir (Panel A), GT1 HCV 200-mg Elbasvir (Panel D), GT1 HCV 5-mg Elbavir (Panel C), GT1a HCV 10-mg Elbasvir (Panel I), GT1a HCV 50-mg Elbasvir (Panel J), GT3 HCV 10-mg Elbasvir (Panel E), GT3 HCV 100-mg Elbasvir (Panel G), GT3 HCV 200-mg Elbasvir (Panel H), GT3 HCV 50-mg Elbasvir (Panel F), GTI HCV 50-g Elbasvir (Panel B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GT1 HCV 10-mg Elbasvir (Panel A), GT1 HCV 200-mg Elbasvir (Panel D), GT1 HCV 5-mg Elbavir (Panel C), GT1a HCV 10-mg Elbasvir (Panel I), GT1a HCV 50-mg Elbasvir (Panel J), GT3 HCV 10-mg Elbasvir (Panel E), GT3 HCV 100-mg Elbasvir (Panel G), GT3 HCV 200-mg Elbasvir (Panel H), GT3 HCV 50-mg Elbasvir (Panel F), GTI HCV 50-g Elbasvir (Panel B)
C: Arm Label: 001 T(q8h) / PR; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated interferon alfa-2a, Drug: Telaprevir | Arm Label: 002 T(b.i.d.) / PR; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Telaprevir, Drug: Pegylated interferon alfa-2a | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 001 T(q8h) / PR, 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 001 T(q8h) / PR, 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): 001 T(q8h) / PR
D: Arm Label: BI201335 12W; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI201335 | Arm Label: BI 201335 24W; Type: EXPERIMENTAL; Interventions: Drug: BI201335 24W, Drug: PegIFN/RBV | Arm Label: BI 201335 24 W; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: Bi 201335 | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 24 W | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI201335 12W | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): BI201335 12W | Intervention Type: DRUG; Name: BI201335 24W; Assigned to Arm(s): BI 201335 24W | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 24W | Intervention Type: DRUG; Name: Bi 201335; Assigned to Arm(s): BI 201335 24 W

Answer: A